other material
confidence high
sentiment positive
materiality 0.80
Trevi reports positive Phase 2 CANAL data: Haduvio reduces daytime cough 75% vs 23% placebo
Trevi Therapeutics, Inc.
- Primary endpoint met: placebo-adjusted daytime cough frequency reduction 52.5% (p<0.0001).
- Haduvio achieved 76.1% reduction in 24-hour cough frequency vs 25.3% placebo (p<0.0001).
- 97% of Haduvio subjects had ≥30% reduction in 24-hour cough vs 35% placebo (p<0.0001).
- Company aims to initiate Phase 2b in chronic cough IPF in H1 2023, Phase 3 in prurigo nodularis in H1 2023.
- Safety consistent with prior trials; most common adverse events: nausea, fatigue, constipation, dizziness.